=> fil reg

FILE 'REGISTRY' ENTERED AT 10:40:55 ON 29 DEC 1998
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 25 DEC 98 HIGHEST RN 216142-46-0
DICTIONARY FILE UPDATES: 28 DEC 98 HIGHEST RN 216142-46-0

TSCA INFORMATION NOW CURRENT THROUGH JUNE 29, 1998

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

=> d stat que l14

L12 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 6
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE
L14 392 SEA FILE=REGISTRY SSS FUL L12

100.0% PROCESSED 1482 ITERATIONS 392 ANSWERS
SEARCH TIME: 00.00.01

=> d his l17-

(FILE 'REGISTRY' ENTERED AT 10:21:38 ON 29 DEC 1998)

FILE 'HCAPLUS' ENTERED AT 10:29:35 ON 29 DEC 1998
L17 268 S L14
E VERE/AU
L18 21 S E14-E19
E SCHINAZI/AU

```
L19          279 S E6-E10,E13
L20            9 S L17 AND L18,L19
L21           91 S L17 AND (SMITHKLINE OR BEECHAM OR KLINE)/PA,CS
L22           91 S L20,L21
L23           59 S L22 AND PENCICLOVIR?
L24            3 S L22 AND PCV
L25            3 S L22 AND PCV?
L26            7 S L23,L24,L25 AND R
L27            2 S L26 AND TRIPHOSPHATE
L28            1 S L26 AND CONFIGURATION
L29           15 S L22 AND BRL()(39123 OR 39 123)
L30            0 S L22 AND BRL39123
L31            6 S L29 AND TRIPHOSPHATE
L32            4 S L29 AND R
L33            8 S L31,L32 NOT L27,L28
L34           91 S L22,L29
L35            2 S L34 AND HEPATIT?
L36            1 S L34 AND HIV
L37            0 S L34 AND AIDS
L38            3 S L34 AND IMMUNODEFICIEN?
L39            7 S L27,L28,L35,L36,L38
                 SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 10:40:16 ON 29 DEC 1998
L40           22 S E1-E22

     FILE 'REGISTRY' ENTERED AT 10:40:55 ON 29 DEC 1998

=> d ide can tot l40


L40  ANSWER 1 OF 22  REGISTRY  COPYRIGHT 1998 ACS
RN   185112-15-6  REGISTRY
CN   6H-Purin-6-one, 2-amino-1,9-dihydro-9-[3-(hydroxymethyl)-4-
     (phosphonooxy)butyl]-, (R)- (9CI)  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C10 H16 N5 O6 P
SR   CA
LC   STN Files:   CA, CAPLUS

Absolute stereochemistry.
```




```
                1 REFERENCES IN FILE CA (1967 TO DATE)
                1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE   1:  126:60295
```

← applicants

L40 ANSWER 2 OF 22 REGISTRY COPYRIGHT 1998 ACS
RN **185112-14-5** REGISTRY
CN 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[3-(hydroxymethyl)-4-(phosphonooxy)butyl]-, (S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H16 N5 O6 P
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:60295

L40 ANSWER 3 OF 22 REGISTRY COPYRIGHT 1998 ACS
RN **185031-53-2** REGISTRY
CN 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-hydroxy-3-[[(4-methoxyphenyl)diphenylmethoxy]methyl]butyl]-, (R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H31 N5 O4
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:60295

L40 ANSWER 4 OF 22 REGISTRY COPYRIGHT 1998 ACS
RN **185031-52-1** REGISTRY

CN 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-hydroxy-3-[[(4-methoxyphenyl)diphenylmethoxy]methyl]butyl]-, (S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H31 N5 O4
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:60295

L40 ANSWER 5 OF 22 REGISTRY COPYRIGHT 1998 ACS
RN **185031-51-0** REGISTRY
CN Diphosphoric acid, mono[4-(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-2-(hydroxymethyl)butyl] ester, (R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H17 N5 O9 P2
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:60295

L40 ANSWER 6 OF 22 REGISTRY COPYRIGHT 1998 ACS
RN **185031-50-9** REGISTRY
CN Triphosphoric acid, P-[4-(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-2-(hydroxymethyl)butyl] ester, (R)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH
MF C10 H18 N5 O12 P3
SR CA
LC STN Files: CA, CAPLUS, TOXLIT

Absolute stereochemistry.



3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:258526

REFERENCE 2: 126:126535

REFERENCE 3: 126:60295

L40 ANSWER 7 OF 22 REGISTRY COPYRIGHT 1998 ACS
RN **185031-49-6** REGISTRY
CN Diphosphoric acid, mono[4-(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-2-(hydroxymethyl)butyl] ester, (S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H17 N5 O9 P2
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:60295

L40 ANSWER 8 OF 22 REGISTRY COPYRIGHT 1998 ACS
RN **185031-48-5** REGISTRY
CN 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[3-(hydroxymethyl)-4-

(phenylmethoxy)butyl]-, (R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H21 N5 O3
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:60295

L40 ANSWER 9 OF 22 REGISTRY COPYRIGHT 1998 ACS
RN **185031-47-4** REGISTRY
CN 9H-Purine-9-butanol, 2-amino-6-chloro-.beta.-[(phenylmethoxy)methyl]-, (R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H20 Cl N5 O2
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:60295

L40 ANSWER 10 OF 22 REGISTRY COPYRIGHT 1998 ACS
RN **185031-45-2** REGISTRY
CN 9H-Purin-2-amine, 6-chloro-9-[3-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-4-(phenylmethoxy)butyl]-, (S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH

MF C33 H38 Cl N5 O2 Si
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:60295

L40 ANSWER 11 OF 22 REGISTRY COPYRIGHT 1998 ACS
RN **185031-38-3** REGISTRY
CN 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[3-(hydroxymethyl)-4-(phenylmethoxy)butyl]-, (S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H21 N5 O3
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:60295

L40 ANSWER 12 OF 22 REGISTRY COPYRIGHT 1998 ACS
RN **185031-37-2** REGISTRY
CN 9H-Purine-9-butanol, 2-amino-6-chloro-.beta.-[(phenylmethoxy)methyl]-, (S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H20 Cl N5 O2
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:60295

L40 ANSWER 13 OF 22 REGISTRY COPYRIGHT 1998 ACS
RN **185031-36-1** REGISTRY
CN 9H-Purin-2-amine, 6-chloro-9-[3-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-4-(phenylmethoxy)butyl]-, (R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C33 H38 Cl N5 O2 Si
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:60295

L40 ANSWER 14 OF 22 REGISTRY COPYRIGHT 1998 ACS
RN **145839-78-7** REGISTRY
CN Triphosphoric acid, P-[4-(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-2-(hydroxymethyl)butyl] ester, (S)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (S)-Penciclovir triphosphate
FS STEREOSEARCH
MF C10 H18 N5 O12 P3
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, EMBASE, TOXLIT

(*File contains numerically searchable property data)

Absolute stereochemistry.



5 REFERENCES IN FILE CA (1967 TO DATE)
5 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:258526

REFERENCE 2: 126:126535

REFERENCE 3: 126:60295

REFERENCE 4: 124:278087

REFERENCE 5: 118:73185

L40 ANSWER 15 OF 22 REGISTRY COPYRIGHT 1998 ACS
RN **130350-12-8** REGISTRY
CN Triphosphoric acid, P-[4-(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-2-(hydroxymethyl)butyl-1-13C] ester, (S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H18 N5 O12 P3
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 113:212538

L40 ANSWER 16 OF 22 REGISTRY COPYRIGHT 1998 ACS
RN **130185-08-9** REGISTRY

CN Triphosphoric acid, P-[4-(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-2-(hydroxymethyl-13C)butyl] ester, (S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H18 N5 O12 P3
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 113:212538

L40 ANSWER 17 OF 22 REGISTRY COPYRIGHT 1998 ACS
RN **130185-07-8** REGISTRY
CN 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)butyl-4-13C]-, (S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H15 N5 O3
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, DRUGPAT, DRUGUPDATES
(*File contains numerically searchable property data)

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 113:212538

L40 ANSWER 18 OF 22 REGISTRY COPYRIGHT 1998 ACS
RN **130185-06-7** REGISTRY
CN 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-hydroxy-3-

(hydroxymethyl)butyl-4-13C]-, (R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H15 N5 O3
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, DRUGPAT, DRUGUPDATES
(*File contains numerically searchable property data)

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 117:171931

REFERENCE 2: 113:212538

L40 ANSWER 19 OF 22 REGISTRY COPYRIGHT 1998 ACS
RN **120082-86-2** REGISTRY
CN Triphosphoric acid, P-[4-(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-2-(hydroxymethyl)butyl] ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C10 H18 N5 O12 P3
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, TOXLIT, USPATFULL
(*File contains numerically searchable property data)



8 REFERENCES IN FILE CA (1967 TO DATE)
8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 129:239501

REFERENCE 2: 126:126535

REFERENCE 3: 123:102118

REFERENCE 4: 122:204641

REFERENCE 5: 122:122582

REFERENCE 6: 121:76931

REFERENCE 7: 116:158943

REFERENCE 8: 110:165605

L40 ANSWER 20 OF 22 REGISTRY COPYRIGHT 1998 ACS
RN **104227-87-4** REGISTRY
CN 1,3-Propanediol, 2-[2-(2-amino-9H-purin-9-yl)ethyl]-, diacetate (ester) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN BRL 42810
CN Famciclovir
FS 3D CONCORD
MF C14 H19 N5 O4
CI COM
SR CA
LC STN Files: ADISINSIGHT, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CBNB, CIN, DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, TOXLINE, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



143 REFERENCES IN FILE CA (1967 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
143 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:57

REFERENCE 2: 129:347286

REFERENCE 3: 129:298376

REFERENCE 4: 129:255005

REFERENCE 5: 129:254234

REFERENCE 6: 129:254233

REFERENCE 7: 129:239917

REFERENCE 8: 129:239916

REFERENCE 9: 129:239915

REFERENCE 10: 129:239914

L40 ANSWER 21 OF 22 REGISTRY COPYRIGHT 1998 ACS
RN **97845-62-0** REGISTRY
CN 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)butyl]-, monosodium salt (9CI) (CA INDEX NAME)
OTHER NAMES:
CN BRL 39123A
CN Penciclovir sodium
MF C10 H15 N5 O3 . Na
SR CA
LC STN Files: CA, CAPLUS, DRUGPAT, DRUGUPDATES, PROMT, RTECS*, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
CRN (39809-25-1)



● Na

6 REFERENCES IN FILE CA (1967 TO DATE)
6 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 118:15910

REFERENCE 2: 114:199655

REFERENCE 3: 112:83948

REFERENCE 4: 112:101

REFERENCE 5: 110:185958

REFERENCE 6: 103:123509

L40 ANSWER 22 OF 22 REGISTRY COPYRIGHT 1998 ACS
RN **39809-25-1** REGISTRY
CN 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)butyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 9-[4-Hydroxy-3-(hydroxymethyl)butyl]guanine
CN BRL 39123
CN Penciclovir
CN VSA 671
FS 3D CONCORD
DR 111790-02-4
MF C10 H15 N5 O3
CI COM
LC STN Files: ADISINSIGHT, AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CIN,

DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, TOXLINE, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



170 REFERENCES IN FILE CA (1967 TO DATE)
13 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
170 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 129:347286

REFERENCE 2: 129:310877

REFERENCE 3: 129:310316

REFERENCE 4: 129:239508

REFERENCE 5: 129:239503

REFERENCE 6: 129:239443

REFERENCE 7: 129:197582

REFERENCE 8: 129:170137

REFERENCE 9: 129:136409

REFERENCE 10: 129:95688

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 10:41:29 ON 29 DEC 1998
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1967 - 29 Dec 1998 VOL 130 ISS 1
FILE LAST UPDATED: 26 Dec 1998 (981226/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGistRY for direct browsing and searching of

all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 10:43:11 ON 29 DEC 1998
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1967 - 29 Dec 1998 VOL 130 ISS 1
FILE LAST UPDATED: 26 Dec 1998 (981226/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d bib abs hitrn tot 139

L39 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 1998 ACS
AN 1998:385513 HCAPLUS
DN 129:49634
TI A combination of penciclovir and .alpha.-interferon for the treatment of **hepatitis** B virus infection
IN Boon, Ronald James; Atkinson, Gillian Frances
PA **Smithkline Beecham** PLC, UK; Boon, Ronald James; Atkinson, Gillian Frances
SO PCT Int. Appl., 11 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9823285	A1	19980604	WO 97-GB3236	19971126
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9851270	A1	19980622	AU 98-51270	19971126
PRAI	GB 96-24801		19961129		
	GB 97-900		19970117		
	WO 97-GB3236		19971126		

AB A method for the treatment or prophylaxis of **hepatitis** B

virus infections in humans or animals comprises administering penciclovir (or a bioprecursor such as famciclovir) and .alpha.-interferon. Two patients suffering from chronic **hepatitis** B virus infection were successfully treated with the combination therapy of famciclovir and .alpha.-interferon.

IT **39809-25-1**, Penciclovir **104227-87-4**, Famciclovir
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(penciclovir and .alpha.-interferon for treatment of **hepatitis** B virus infection in humans)

L39 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 1998 ACS
AN 1997:513561 HCAPLUS
DN 127:171594
TI Nucleoside analogs in combination therapy of herpes simplex infections
IN Boyd, Malcolm Richard
PA **Smithkline Beecham** Plc, UK; Boyd, Malcolm Richard
SO PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9726882	A1	19970731	WO 97-GB226	19970124
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9715506	A1	19970820	AU 97-15506	19970124
	EP 876146	A1	19981111	EP 97-901694	19970124
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	NO 9803402	A	19980723	NO 98-3402	19980723
PRAI	GB 96-1544	19960126			
	WO 97-GB226	19970124			

AB A pharmaceutical product comprising a nucleoside analog active against herpes simplex virus, such as acyclovir/valaciclovir or penciclovir/famciclovir, and an immunosuppressant, as a combined prepn. for simultaneous, sep. or sequential use in the treatment and/or prevention of herpes simplex virus infections. Cyclosporin A in combination with famciclovir or valaciclovir had greater effects in mice than the nucleosides alone.

IT **39809-25-1**, Penciclovir **104227-87-4**, Famciclovir
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleoside analogs in combination therapy of herpes simplex infections)

L39 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 1998 ACS
AN 1997:34050 HCAPLUS
DN 126:60295
TI Preparation of (**R**)-**penciclovir**

triphosphate as virucide
IN **Vere, Hodge Richard Anthony; Schinazi, Raymond F.**
PA **Smithkline Beecham** Plc, UK; Vere Hodge, Richard Anthony; Schinazi, Raymond F.
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9633720	A1	19961031	WO 96-EP1706	19960423
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 822817	A1	19980211	EP 96-914109	19960423
R: BE, CH, DE, ES, FR, GB, IT, LI, NL				

PRAI GB 95-8237 19950424
GB 96-4909 19960308
WO 96-EP1706 19960423
GI



I

AB Acyclic nucleotides, e.g. I, were prepd. as virucides (no data).
IT **185031-36-1P 185031-37-2P 185031-38-3P 185031-45-2P 185031-47-4P 185031-48-5P 185031-52-1P 185031-53-2P**
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of (**R**)-**penciclovir triphosphate** as virucide)
IT **145839-78-7P 185031-49-6P 185031-50-9P 185031-51-0P 185112-14-5P 185112-15-6P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of (**R**)-**penciclovir triphosphate** as virucide)

L39 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 1998 ACS
AN 1995:746322 HCAPLUS
DN 123:132851
TI Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 7 infection
IN **Vere Hodge, Richard Anthony**
PA **SmithKline Beecham** PLC, UK
SO PCT Int. Appl., 11 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9513074	A1	19950518	WO 94-GB2486	19941111
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9408908	A	19950817	ZA 94-8908	19941110
	CA 2176392	AA	19950518	CA 94-2176392	19941111
	AU 9481491	A1	19950529	AU 94-81491	19941111
	AU 696833	B2	19980917		
	EP 728002	A1	19960828	EP 95-900830	19941111
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1136277	A	19961120	CN 94-194328	19941111
	JP 09511218	T2	19971111	JP 94-513697	19941111
PRAI	GB 93-23404	19931112			
	WO 94-GB2486	19941111			

AB Amino purine derivs. or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl deriv. of 2-amino purine are used in the manuf. of a medicament for prophylaxis or treatment of HHV-7 infection. Human mononuclear cells were infected with human herpes virus and treated with 100 .mu.M penciclovir. The amt. of virus was decreased by 31% after 7 days.
IT **39809-25-1**, Penciclovir **104227-87-4**, Famciclovir
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino purine derivs. for the treatment and prophylaxis of human herpes virus 7 infection)

L39 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 1998 ACS
AN 1992:158943 HCAPLUS
DN 116:158943
TI Pharmaceutical compositions containing penciclovir, famciclovir, and related guanine derivatives for the treatment of the **HIV**-1 infections
IN Kenig, Martin David John; **Vere Hodge, Richard Anthony**
PA **Beecham** Group PLC, UK
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9200742	A1	19920123	WO 91-GB1082	19910703
	W: AU, CA, HU, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	CA 2086756	AA	19920108	CA 91-2086756	19910703
	AU 9181032	A1	19920204	AU 91-81032	19910703
	AU 647807	B2	19940331		
	EP 538305	A1	19930428	EP 91-912424	19910703

	EP 538305	B1	19970409		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05507719	T2	19931104	JP 91-511884	19910703
	JP 2764656	B2	19980611		
	AT 151291	E	19970415	AT 91-912424	19910703
	ES 2101747	T3	19970716	ES 91-912424	19910703
	ZA 9105214	A	19920624	ZA 91-5214	19910705
	IL 98749	A1	19950330	IL 91-98749	19910705
	US 5674869	A	19971007	US 95-469273	19950606
PRAI	GB 90-15051	19900707			
	WO 91-GB1082	19910703			
	US 93-971917	19930128			
	US 94-237936	19940502			
	US 95-380226	19950127			

OS MARPAT 116:158943

AB Pharmaceutical compns. contg. guanine derivs. and prodrugs thereof such as penciclovir (I) are used for treatment of **HIV**-1 infection. The amt. of I.triphosphate required to give 50% inhibition of **HIV**-1 reverse transcriptase was .apprx.4.mu.M.

IT **39809-25-1**, Penciclovir **39809-25-1D**, Penciclovir, sodium salt hydrate **104227-87-4**, Famciclovir **120082-86-2**
RL: BIOL (Biological study)
(**HIV** infection treatment with pharmaceutical compns. contg.)

L39 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 1998 ACS

AN 1991:199655 HCAPLUS

DN 114:199655

TI Derivatives of penciclovir for the treatment of **hepatitis** B infections

IN Boyd, Malcolm Richard; Sutton, David

PA **Beecham** Group PLC, UK

SO Eur. Pat. Appl., 5 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 388049	A2	19900919	EP 90-302186	19900301
	EP 388049	A3	19911106		
	EP 388049	B1	19950517		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2011238	AA	19900903	CA 90-2011238	19900301
	AU 9050600	A1	19901101	AU 90-50600	19900301
	AU 628137	B2	19920910		
	HU 53522	A2	19901128	HU 90-1252	19900301
	HU 205715	B	19920629		
	ZA 9001572	A	19910327	ZA 90-1572	19900301
	IL 93594	A1	19950526	IL 90-93594	19900301
	ES 2072386	T3	19950716	ES 90-302186	19900301
	JP 02275821	A2	19901109	JP 90-49722	19900302
	JP 2513519	B2	19960703		
	LV 10923	B	19960620	LV 95-253	19950816
PRAI	GB 89-4855	19890303			

OS MARPAT 114:199655

GI



I

AB Penciclovir and the prodrugs I (X = H, C1-6 alkoxy, NH2) are agents for the treatment of **hepatitis** B. Also usable are salts, phosphate esters and/or acyl derivs. of the above compds. Oral administration of 100 mg penciclovir/kg, twice daily for 3 wk strongly reduced the concn. of **hepatitis** virus DNA and DNA polymerase, in ducks.

IT **39809-25-1**, Penciclovir **97845-62-0**
104227-87-4, Famciclovir
RL: BIOL (Biological study)
(**hepatitis** B treatment by)

L39 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 1998 ACS
AN 1990:612538 HCAPLUS
DN 113:212538
TI Synthesis of isotopically chiral [13C]**penciclovir** (BRL 39123) and its use to determine the absolute **configuration** of **penciclovir triphosphate** formed in herpes virus infected cells
AU Jarvest, Richard L.; Barnes, Roger D.; Earnshaw, David L.; O'Toole, Kevin J.; Sime, John T.; Hodge, R. Anthony Vere
CS **Beecham** Pharm. Res. Div., Epsom/Surrey, KT18 5XQ, UK
SO J. Chem. Soc., Chem. Commun. (1990), (7), 555-6
CODEN: JCCCAT; ISSN: 0022-4936
DT Journal
LA English
GI



I

AB Isotopically chiral [13C]**penciclovir** (BRL 39123) [(**R**)- and (S)-I] was synthesized via a stereospecific hydrolysis catalyzed by the lipase from Candida cylindraceae. Anal. by 13C NMR showed that the **triphosphate** of **penciclovir** formed in herpes simplex type 1-infected cells has (S) stereochem. with an enantiomeric purity of >95%.

IT **130185-08-9P 130350-12-8P**
RL: FORM (Formation, nonpreparative); PREP (Preparation)
(formation of, in herpes virus-infected cells)
IT **130185-06-7P 130185-07-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and phosphorylation of, in herpes virus-infected cells)

=> fil reg

FILE 'REGISTRY' ENTERED AT 10:44:52 ON 29 DEC 1998
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 25 DEC 98 HIGHEST RN 216142-46-0
DICTIONARY FILE UPDATES: 28 DEC 98 HIGHEST RN 216142-46-0

TSCA INFORMATION NOW CURRENT THROUGH JUNE 29, 1998

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

=> d ide can 142

L42 ANSWER 1 OF 1 REGISTRY COPYRIGHT 1998 ACS
RN **185031-50-9** REGISTRY
CN **Triphosphoric acid, P-[4-(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-2-(hydroxymethyl)butyl] ester, (R)- (9CI)** (CA INDEX NAME)
FS STEREOSEARCH
MF **C10 H18 N5 O12 P3**
SR CA
LC STN Files: CA, CAPLUS, TOXLIT

Absolute stereochemistry.



3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:258526

REFERENCE 2: 126:126535

REFERENCE 3: 126:60295

=> d his 142-

(FILE 'REGISTRY' ENTERED AT 10:43:38 ON 29 DEC 1998)
L42 1 S L41 AND R
L43 5 S L14 AND 3/P
L44 0 S L43 NOT L41

FILE 'HCAOLD' ENTERED AT 10:44:29 ON 29 DEC 1998
L45 0 S L42

FILE 'HCAPLUS' ENTERED AT 10:44:32 ON 29 DEC 1998
L46 3 S L42
L47 2 S L46 NOT L39

FILE 'USPATFULL' ENTERED AT 10:44:46 ON 29 DEC 1998
L48 0 S L42

FILE 'REGISTRY' ENTERED AT 10:44:52 ON 29 DEC 1998

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 10:44:59 ON 29 DEC 1998

FILE COVERS 1967 - 29 Dec 1998 VOL 130 ISS 1
FILE LAST UPDATED: 26 Dec 1998 (981226/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d 147 bib abs hitrn tot

L47 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 1998 ACS
AN 1997:182558 HCAPLUS
DN 126:258526
TI Inhibitory effect of penciclovir-triphosphate on duck hepatitis B virus reverse transcription
AU Dannaoui, E.; Trepo, C.; Zoulim, F.
CS INSERM, Lyon, 69003, Fr.
SO Antiviral Chem. Chemother. (1997), 8(1), 38-46
CODEN: ACCHEH; ISSN: 0956-3202
PB International Medical Press
DT Journal
LA English
AB The aim of this study was to investigate the mechanism of inhibition of hepatitis B virus replication by penciclovir-triphosphate, the active metabolite of famciclovir. A recently developed in vitro

translation assay for the expression of an enzymically active duck hepatitis B virus (DHBV) reverse transcriptase was used to assess the inhibitory activity of penciclovir-triphosphate (PVC-TP) in comparison with other guanosine analog triphosphates. Acyclovir-triphosphate (ACV-TP), the chiral triphosphates of penciclovir (PCV), (R)-PCV-TP and (S)-PCV-TP, and carbocyclic-2'-deoxyguanosine-TP (CDG-TP) did inhibit reproducibly minus strand DNA synthesis to different extents. CDG-TP was the most potent inhibitor of dGTP incorporation. The inhibitory effect of these compds. against the incorporation of the first nucleotide of minus strand DNA, dGMP, was similar to that obsd. with DNA chain elongation. 2',3'-Dideoxyguanosine-TP (ddG-TP), ACV-TP and both (R) and (S)-PCV-TP inhibited the incorporation of the next nucleotides in the short DNA primer, whereas CDG-TP did not. These results demonstrated that PVC-TP inhibits hepadnavirus reverse transcription by inhibiting the synthesis of the short DNA primer. The data obtained with the inhibition of the enzymic activity of the DHBV polymerase provides a new insight into the mechanism of action of penciclovir-triphosphate on HBV replication.

IT **185031-50-9**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitory effect of penciclovir-triphosphate on duck hepatitis B virus reverse transcription)

L47 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 1998 ACS
AN 1997:92431 HCAPLUS
DN 126:126535
TI Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir
AU Shaw, Tim; Mok, Su San; Locarnini, Stephen A.
CS Victorian Infectious Diseases Reference Laboratory, Fairfield Hospital, Victoria, 3078, Australia
SO Hepatology (Philadelphia) (1996), 24(5), 996-1002
CODEN: HPTLD9; ISSN: 0270-9139
PB Saunders
DT Journal
LA English
AB The deoxyguanosine analog penciclovir (PCV; 9-[4-hydroxy-3-hydroxymethyl-but-1-yl]guanine), has shown potent antiviral activity against herpes viruses and hepadnaviruses. Efficacy against chronic hepatitis B virus (HBV) infection has been demonstrated in an animal model and in recent clin. trials of famciclovir, the oral form of PCV. The antiviral activity of PCV is believed to be dependent on the intracellular formation of PCV-triphosphate (PCV-TP) which is presumed to inhibit HBV replication by interfering with viral DNA polymerase activity. The (S)-enantiomer is preferentially formed in herpes virus-infected cells, and is the more active against the herpes simplex virus; however, little is known about the biochem. mechanisms of PCV phosphorylation or of interference with viral replication in HBV-infected cells. Here, we report that in contrast with herpes simplex virus, the (R)-enantiomer of PCV-TP is a more potent inhibitor of HBV DNA polymerase-reverse transcriptase (pol-RT) in vitro than the (S)-enantiomer. In assays for HBV DNA pol-RT activity, in which purified viral core particles were the enzyme source, the IC50s for (R- and S)-enantiomers of PCV-TP were 2.5 .mu.mol/L and 11 .mu.mol/L, resp. The estd. Kis for (R)- and (S)- PCV-TP were .apprxeq.0.03 .mu.mol/L and .apprxeq.0.04

.mu.mol/L, resp., about 3-fold lower than the Km for deoxy-guanosine triphosphate (dGTP) in the same system. In addn., we report that PCV metab. is similar in both control (HepG2) and in HBV-transfected (2.2.15) hepatoblastoma cells in vitro, indicating that cellular enzyme(s) catalyze PCV phosphorylation. Peak PCV-TP concns. of about .4 .mu.mol/L were reached in both cell types in less than 12 h, and intracellular PCV-TP was exceptionally stable with half-life of about 18 h. These observations provide a mechanistic basis for the potent activity of PCV against HBV.

IT **185031-50-9**

RL: ANT (Analyte); BAC (Biological activity or effector, except adverse); MFM (Metabolic formation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)

(inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate)